



Biosign Announces Private Placement to Raise \$4.5 Million

TORONTO, ONTARIO, Tuesday, March 02, 2010 – Biosign Technologies Inc. (**CNSX: BIO**) (the “Company” or “Biosign”) today announced that it intends to raise gross proceeds of up to CDN \$4.5 million through a brokered private placement of common shares of the Company (the “Shares”) at a price of 75 cents per common share (the “Offering”). The Company has retained Dundee Securities Corporation to act as lead placement agent along with Canaccord Financial Inc. as co-agent.

Proceeds from the Offering are intended to be used as working capital to support commercialization of the Company’s products and services, with emphasis on non-invasive monitoring of blood pressure and blood glucose, and for general corporate purposes.

The Shares to be issued in connection with this Offering will be subject to a four month hold period from the share issuance date in accordance with the policies of the Canadian National Stock Exchange (CNSX Markets Inc.) and applicable securities laws. The Offering is subject to all necessary regulatory and stock exchange approvals. Closing of the Offering will be on or about March 25, 2010.

Contact:

Radu Leca, President & CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
Email: ceo@biosign.com

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT[®] medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit <http://www.biosign.com>.

The CNSX has neither approved nor disapproved the contents of this press release.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES